TAs and tumor-associated antigens (TAAs) are processed by mature DCs and presented as major histocompatibility complex I molecules to CD8+ T cells, generating CTLs for tumor-specific immune responses, leading to tumor regression [21]. The gene discussed is CD8A; the disease is neoplasm.